Abstract Library

#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cella D

Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,

Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,